Back to results
US 5,965,709 AGranted
IgE antagonists
AssigneeGenentech, Inc.
InventorsLeonard G. Presta, Paula M. Jardieu
Life of this patent
Estimating the term…
Abstract
IgE antagonists comprising one or more of the Fc.sub..epsilon. RI receptor-binding determinant sites of human IgE are described. The disclosed antagonists include IgE variants, peptide antagonists, peptidomimetics and other small molecules. The antagonists are useful in raising and screening anti-IgE antibodies, in the isolation and purification of Fc.sub..epsilon. RI receptor, and in the treatment of allergic disease.
Claims8
An IgE variant comprising an immunoglobulin template and binding determinant sequences CD.sub.bds, EF.sub.bds and Arg-Ala-Leu-Met (SEQ ID NO:
- 15) which have been substituted for the analogous template sequences, wherein:
- a) CD.sub.bds is selected from the group consisting of:
- Arg-Ala-Ser-Gly-Lys (SEQ ID NO:
- 1);
- Arg-Ala-Ser-Gly-Lys-Pro (SEQ ID NO:
- 2);
- Arg-Ala-Ser-Gly-Lys-Pro-Val (SEQ ID NO:
- 3);
- Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn (SEQ ID NO:
- 4);
- Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn-His (SEQ ID NO:
- 5);
- Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn-His-Ser (SEQ ID NO:
- 6);
- Ser-Arg-Ala-Ser-Gly-Lys-Pro (SEQ ID NO:
- 7);
- Ser-Arg-Ala-Ser-Gly-Lys-Pro-Val (SEQ ID NO:
- 8);
- Ser-Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn (SEQ ID NO:
- 9);
- Ser-Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn-His (SEQ ID NO:
- 10);
- and
- Ser-Arg-Ala-Ser-Gly-Lys-Pro-Val-Asn-His-Ser (SEQ ID NO:
- 11);
- b) EF.sub.bds is selected from the group consisting of:
- Asp-Trp-Ile-Glu-Gly-Glu-Thr (SEQ ID NO:
- 12);
- Arg-Asp-Trp-Ile-Glu-Gly-Glu-Thr (SEQ ID NO:
- 13);
- and
- Thr-Arg-Asp-Trp-Ile-Glu-Gly-Glu-Thr (SEQ ID NO:
- 14).
30 more elements
Dependencies are inferred from the claim text.